Sandoz settles pricing suits with Florida, California

Novartis' ($NVS) generics unit Sandoz has agreed to pay $150 million to settle pricing-fraud lawsuits filed by the states of Florida and California. It's the latest settlement in ongoing probes of average wholesale pricing in the pharma industry. Report

Suggested Articles

The Trump administration has selected five COVID-19 vaccines for Operation Warp Speed, the NYT reports, with Big Pharma dominating the list.

Racing with some COVID-19 vaccine heavyweights, Novavax has brought on a partner to manufacture adjuvant for its in-development shot. 

Bristol Myers Squibb's Zeposia will leverage promising top-line phase 3 data into a possible FDA approval in the lucrative ulcerative colitis market.